-+ 0.00%
-+ 0.00%
-+ 0.00%

*Candel Therapeutics: Cash, Cash Equivalents of $194.8M, as of March 31, 2026, Expected Sufficient to Fund Co's Current Operating Plan Into Q1 2028 >CADL

Dow Jones·05/14/2026 12:10:00

Please log in to view news